CEBP CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nock, N. L.
Right arrow Articles by Witte, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nock, N. L.
Right arrow Articles by Witte, J. S.
Cancer Epidemiology Biomarkers & Prevention Vol. 15, 756-761, April 2006
© 2006 American Association for Cancer Research

Polymorphisms in Polycyclic Aromatic Hydrocarbon Metabolism and Conjugation Genes, Interactions with Smoking and Prostate Cancer Risk

Nora L. Nock1, Xin Liu4, Mine S. Cicek5, Li Li2, Flavius Macarie5, Benjamin A. Rybicki6, Sarah J. Plummer5, Gregory T. MacLennan3, Graham Casey5 and John S. Witte4

Departments of 1 Epidemiology and Biostatistics, 2 Family Medicine, and 3 Pathology, Case Western Reserve University, Cleveland, Ohio; 4 Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California; 5 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio; and 6 Department of Biostatistics and Research Epidemiology, Henry Ford Health System, Detroit, Michigan

Requests for reprints: John S. Witte, Department of Epidemiology and Biostatistics, University of California, San Francisco, 500 Parnassus Avenue, MU-420 West, San Francisco, CA 94143-0506. Phone: 415-502-6882; Fax: 415-476-6014. E-mail: jwitte{at}itsa.ucsf.edu

The relationship between cigarette smoking and prostate cancer remains unclear. Any potential association may depend on the individuals' ability to metabolize and detoxify cigarette carcinogens—such as polycyclic aromatic hydrocarbons. To investigate this, we studied the association between prostate cancer and smoking, as well as the main and modifying effects of functional polymorphisms in genes that metabolize polycyclic aromatic hydrocarbons (CYP1A1 Ile462Val, microsomal epoxide hydrolase His139Arg) and detoxify reactive derivatives (GSTM1 null deletion, GSTT1 null deletion, GSTP1 Ile105Val and Ala114Val) using a family-based case-control design (439 prostate cancer cases and 479 brother controls). Within the entire study population, there were no main effects for smoking or any of the polymorphisms. However, the nondeleted GSTM1 allele was inversely associated with prostate cancer [odds ratio (OR), 0.50; 95% confidence interval (95% CI), 0.26-0.94] among men with less aggressive disease (Gleason score < 7 and clinical tumor stage < T2c) and positively associated (OR, 1.68; 95% CI, 1.01-2.79) with prostate cancer in men with more aggressive disease (Gleason score ≥ 7 or clinical tumor stage ≥ T2c). We also found a statistically significant negative multiplicative interaction between the GSTM1 nondeleted allele and heavy smoking (> 20 pack-years) in the total study population (P = 0.01) and in Caucasians (P = 0.01). Among Caucasians, heavy smoking increased prostate cancer risk nearly 2-fold in those with the GSTM1 null genotype (OR, 1.73; 95% CI, 0.99-3.05) but this increased risk was not observed in heavy smokers who carried the GSTM1 nondeleted allele (OR, 0.95; 95% CI, 0.53-1.71). Our results highlight the importance of considering genetic modifiers of carcinogens when evaluating smoking in prostate cancer. (Cancer Epidemiol Biomarkers Prev 2006;15(4):765–61)




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
B. A. Rybicki, C. Neslund-Dudas, C. H. Bock, A. Rundle, A. T. Savera, J. J. Yang, N. L. Nock, and D. Tang
Polycyclic Aromatic Hydrocarbon-DNA Adducts in Prostate and Biochemical Recurrence after Prostatectomy
Clin. Cancer Res., February 1, 2008; 14(3): 750 - 757.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. Koutros, A. J. Cross, D. P. Sandler, J. A. Hoppin, X. Ma, T. Zheng, M. C.R. Alavanja, and R. Sinha
Meat and Meat Mutagens and Risk of Prostate Cancer in the Agricultural Health Study
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 80 - 87.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
N. L. Nock, D. Tang, A. Rundle, C. Neslund-Dudas, A. T. Savera, C. H. Bock, K. G. Monaghan, A. Koprowski, N. Mitrache, J. J. Yang, et al.
Associations between Smoking, Polymorphisms in Polycyclic Aromatic Hydrocarbon (PAH) Metabolism and Conjugation Genes and PAH-DNA Adducts in Prostate Tumors Differ by Race
Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1236 - 1245.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2006 by the American Association for Cancer Research.